ProgressImage ProgressImage
Alkem Laboratories Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code 539523 border-img ISIN Demat INE540L01014 border-img Book Value 1,170.81 border-img NSE Symbol ALKEM border-img Div & Yield % 1 border-img Market Cap ( Cr.) 63369.45 border-img P/E 28.27 border-img EPS 187.45 border-img Face Value 2
ParticularsMar 2026
()
Mar 2025
()
Mar 2024
()
Mar 2023
()
Mar 2022
()
Mar 2021
()
INCOME :       
Sales Turnover 9690.188831.137972.259054.558829.817219.68
Excise Duty 0.000.000.000.000.000.00
Net Sales 9690.188831.137972.259054.558829.817219.68
Other Income 666.43698.23492.63266.29199.89190.01
Stock Adjustments 45.67-56.6130.85-257.73360.90301.29
Total Income 10402.289472.758495.739063.119390.607710.98
EXPENDITURE :       
Raw Materials 2856.282785.532654.633572.913926.792966.31
Power & Fuel Cost 126.89128.35123.85126.32129.53100.12
Employee Cost 1883.031630.96737.581516.221434.491158.72
Other Manufacturing Expenses 489.49509.57439.03361.12399.80280.51
Selling & Administrative Expenses 1904.991673.041617.161739.711438.801007.42
Miscellaneous Expenses 208.16-109.13823.50103.5950.9471.74
Less : Pre-operative Expenses Capitalised 0.000.000.000.000.000.00
Total Expenditure 7468.846618.326395.757419.877380.355584.82
Operating Profit 2933.442854.432099.981643.242010.252126.16
Interest 57.2976.1180.0786.4037.9042.93
Gross Profit 2876.152778.322019.911556.841972.352083.23
Depreciation 256.56283.61239.14229.85218.98198.93
Profit Before Tax 2619.592494.711780.771326.991753.371884.30
Tax 432.00350.1332.82227.52303.82331.83
Fringe Benefit tax 0.000.000.000.000.000.00
Deferred Tax -94.50-136.310.80-35.00-91.70-132.61
Reported Net Profit 2282.092280.891747.151134.471541.251685.08
Extraordinary Items -119.755.56-57.92-10.241.8216.49
Adjusted Net Profit 2401.842275.331805.071144.711539.431668.59
Adjustment below Net Profit 0.000.000.000.000.000.00
P & L Balance brought forward 10419.608640.887431.776823.395700.624350.32
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 609.78502.17538.04526.09418.48334.78
P & L Balance carried down 12091.9110419.608640.887431.776823.395700.62
Dividend 0.000.000.000.000.000.00
Preference Dividend 0.000.000.000.000.000.00
Equity Dividend % 2650.002250.002000.002500.001700.001500.00
Dividend Per Share(Rs) 53.0045.0040.0050.0034.0030.00
Earnings Per Share-Unit Curr 190.89190.79146.1494.90128.92140.95
Earnings Per Share(Adj)-Unit Curr 190.89190.79146.1494.90128.92140.95
Book Value-Unit Curr 1170.951030.68882.86782.09731.38637.87
Book Value(Adj)-Unit Curr 1170.951030.68882.86782.09731.38637.87
`

ATTENTION INVESTORS : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day ...Issued in the interest of investors.   Prevent Unauthorized Transactions in your demat account Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day...... issued in the interest of investors.    KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.      No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment.No worries for refund as the money remains in investor's account.

Investor Protection and Arbitration Exchange Circulars and Rules - NSE BSE

Filing of complaints on SCORES – Easy & quick   |    Advisory for Investors   |    AP Details - NSE   |    AP Details - BSE   |    AP Details - MCX
KYC Process Flow   |    Investor Grievance Redressal Process Flow   |   Online Grievance Redressal   |    Voluntary Freezing/Blocking of Trading Account   |    Website Accessibility Statement   |    CDSL MyEasi   |    TRAI Notice on UCC   |    SEBI Risk Disclosure   |    Investor Notice

Disclaimer : Investment in securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

x
x
×
Let's Chat
imsl-img
close
refresh